Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Study for HER2-Overexpressed Metastatic Breast Cancer Patients Treated by Trastuzumab( Cipterbin®) Plus vinorelbinE Simultaneously or Sequencely

NCT01291667 is registered in ClinicalTrials.gov with Shanghai CP Guojian Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT01291667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01291667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Study for HER2-Overexpressed Metastatic Breast Cancer Patients Treated by Trastuzumab( Cipterbin®) Plus vinorelbinE Simultaneously or Sequencely
Lead sponsor
Shanghai CP Guojian Pharmaceutical Co., Ltd.
Phase
Observational
Overall status
Completed
Start date
May 31, 2009
Completion date
Not reported
Enrollment
330 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

adverse events, overall response rate, progress-free survival